Caribou Biosciences announces positive results from its ongoing ANTLER phase 1 clinical trial evaluating vispacabtagene regedleucel, an allogeneic anti-CD19 CAR-T cell therapy, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (2.42)
- Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-term follow-up on patients who received optimized vispa-cel (N=35).
- 82% ORR, 64% CR rate, 51% PFS at 12 months in patients prospectively enrolled in partial HLA matching confirmatory cohort (N=22).
- 86% ORR, 63% CR rate, 53% PFS at 12 months in patients who received vispa-cel with an optimized profile (N=35).
- Vispa-cel is generally well-tolerated, allowing for administration in the outpatient setting.
- Data highlight vispa-cel's potential as best-in-class allogeneic CAR-T cell therapy for LBCL.
- Conference call and webcast scheduled for today at 8:00 am ET